Paradigm Health today announced its role in the execution of a multicenter, hybrid, observational post-marketing commitment study in the United States evaluating an FDA-approved therapy in patients ...

Today, Paradigm Health announced the launch of a landmark research collaboration with the U.S. Food & Drug Administration (FDA) focused on advancing a new model to accelerate clinical trial execution ...

Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has secured US Medicare reimbursement eligibility for eligible procedures in its global pivotal PARADIGM Trial, a prospective, randomised controlled ...

Anteris Technologies is developing DurAVR, a differentiated biomimetic TAVR device with encouraging early clinical data in over 130 patients. AVR’s PARADIGM pivotal trial is the central catalyst. This ...